ABIVAX Société Anonyme (ABVX)
NASDAQ: ABVX · Real-Time Price · USD
109.87
-2.03 (-1.81%)
At close: Apr 28, 2026, 4:00 PM EDT
110.75
+0.88 (0.80%)
After-hours: Apr 28, 2026, 5:16 PM EDT
Company Description
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease.
The company was incorporated in 2013 and is headquartered in Paris, France.
ABIVAX Société Anonyme
| Country | France |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 69 |
| CEO | Marc M. de Garidel |
Contact Details
Address: 7-11 Boulevard Haussmann Paris, 75009 France | |
| Phone | 33 1 53 83 09 63 |
| Website | abivax.com |
Stock Details
| Ticker Symbol | ABVX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $11.60 |
| CIK Code | 1956827 |
| CUSIP Number | 00370M103 |
| ISIN Number | US00370M1036 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marc M. P. de Garidel M.B.A. | Chief Executive Officer and Director |
| Didier Blondel | EVice President, Chief Financial Officer and Board Secretary |
| Patrick Malloy | Senior Vice President of Investor Relations |
| Ida Hatoum | Chief People and Compliance Officer |
| Pierre Courteille M.B.A. | Chief Business Officer |
| Jerome Denis Ph.D. | Executive Vice President of Process Development and Manufacturing |
| Hema Keshava | Senior Vice President of Finance |
| Chris Rabbat Ph.D. | Vice President and Global Head of Medical Affairs |
| Kevin Shan Ph.D. | Vice President and Global Head of Biometrics |
| Mary Mantock | Senior Vice President and Global Head of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 20, 2026 | 6-K | Report of foreign issuer |
| Mar 23, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 23, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Mar 23, 2026 | 6-K | Report of foreign issuer |
| Feb 23, 2026 | 6-K | Report of foreign issuer |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Jan 14, 2026 | SCHEDULE 13D/A | Filing |
| Jan 8, 2026 | 144 | Filing |
| Dec 15, 2025 | 6-K | Report of foreign issuer |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |